微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 32.22% | -8.02% | -0.61% | 108/159 | 50.7% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 32.42% | -6.62% | 13.99% | 108/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 28.44% | -16.63% | -23.7% | 117/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 37.27% | -3.77% | 6.41% | 98/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 35.03% | 1.44% | 0.91% | 102/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 34.72% | -2.05% | 1.77% | 107/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 34.11% | -10.67% | -11.93% | 104/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 38.73% | -4.77% | 12.17% | 105/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 34.53% | -15.64% | -2.57% | 108/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 35.44% | -17.5% | -7.19% | 105/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 38.19% | -13.11% | -6.12% | 99/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 40.68% | 4.42% | -0.64% | 103/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 40.94% | 5.92% | -4.71% | 100/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 42.96% | 11.19% | -2.25% | 97/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 43.95% | 13.15% | 12.82% | 92/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 38.96% | -1.34% | 0.8% | 104/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 38.65% | -1.27% | 0.03% | 100/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 38.64% | -3.34% | -0.53% | 103/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 38.84% | -4.84% | -1.63% | 97/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 39.49% | 0.83% | 0.87% | 106/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 39.15% | -3.67% | -2.06% | 95/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 39.97% | -4.63% | -2.07% | 100/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 40.82% | -2.7% | 4.23% | 83/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 39.16% | -10.14% | -3.63% | 106/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 40.64% | -7.44% | -3.04% | 88/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 41.91% | -6.3% | -0.1% | 90/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 41.95% | -7.49% | -3.73% | 78/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 43.58% | 5.32% | -0.74% | 88/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 43.9% | 7.05% | -1.85% | 70/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 44.73% | 6.13% | -1.37% | 71/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 45.35% | 11.93% | 9.6% | 65/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 41.38% | 4.64% | 0.89% | 90/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 41.01% | 14.56% | -2.69% | 69/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 42.14% | 20.32% | 4.02% | 68/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 40.51% | 20.03% | 2.46% | 71/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 39.54% | 25.3% | 10.45% | 77/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 35.8% | 16.5% | 2.21% | 68/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 35.03% | 10.74% | 3.77% | 73/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 33.75% | 5.37% | 6.96% | 60/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 31.56% | 18.95% | 2.7% | 87/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 30.73% | 8.86% | -2.85% | 61/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 31.63% | 9.94% | -1.26% | 67/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 32.03% | 15.05% | 20.74% | 55/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |